| Talk title | Precision Medicine for Cell Therapy in ARDS |
| Speaker | Prof. Haibo ZHANG
Professor |
| Date & Time | 22 March 2019 (Fri) 15:00-16:00 |
| Venue | Room G002, N22 Building (University of Macau) |
| Abstract | There are controversial reports on applications of mesenchymal stromal cells (MSCs) in patients with acute respiratory distress syndrome (ARDS). We hypothesized that lung microenvironment was the main determinant of beneficial versus detrimental effects of MSCs during ARDS. Distinct proteomic profiles were achieved in three lung injury models. Administration of MSCs protected lung from ventilator-induced injury, while it worsened acidprimed lung injuries associated with fibrotic development in lung environment that had high levels of IL-6 and fibronectin along with low antioxidant capacity. Correction of microenvironment with glutathione peroxidase-1 (GPx-1); or treatment with MSCs carrying human gene of interleukin-10 (MSCIL-10) or hepatocyte growth factor GPx-1 after acid-primed injury, reversed the detrimental effects of native MSCs. Proteomic profiles obtained in the mouse models were also similarly observed in human ARDS. Treatment with the inhibitory cocktail in samples of ARDS patients retained protective effects of MSCs in SAECs. MSCs can be beneficial or detrimental depending on microenvironment at the time of administration. Identification of potential beneficiaries appears to be crucial to guide MSC therapy in ARDS. |